Sunitinib [sunitinib]
- Terms
-
sunitinib malát
Sutent
-
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU 011248
SU 11248
SU-011248
SU-11248
SU011248
SU11248
Sunitinib Malate
Sutent
An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA.
- DUI
- D000077210 MeSH Browser
- CUI
- M0448793
- History note
- 2019 (2003)
- Public note
- 2019; SUNITINIB was indexed under INDOLES and PYRROLES 2003-2018
Allowable subheadings
- AD
- administration & dosage 31
- AE
- adverse effects 26
- AG
- agonists 0
- AA
- analogs & derivatives 0
- AN
- analysis 1
- AI
- antagonists & inhibitors 0
- BL
- blood 0
- CF
- cerebrospinal fluid 0
- CS
- chemical synthesis 0
- CH
- chemistry 0
- CL
- classification 0
- EC
- economics 0
- HI
- history 0
- IM
- immunology 0
- IP
- isolation & purification 0
- ME
- metabolism 0
- PK
- pharmacokinetics 3
- PD
- pharmacology 18
- PO
- poisoning 0
- RE
- radiation effects 0
- ST
- standards 0
- SD
- supply & distribution 0
- TU
- therapeutic use 56
- TO
- toxicity 0
- UR
- urine 0